Posted by Michael Wonder on 17 Jul 2024
CSL Behring announces positive reimbursement decision in Canada for Hemgenix (etranacogene dezaparvovec), the first gene therapy for haemophilia B
16 July 2024 - The positive decision from CADTH recognises the importance of this one-time, single dose innovative treatment for adults with haemophilia B who require routine prophylaxis.
CSL Behring Canada today announced that the CADTH Canadian Drug Expert Committee recommended public drug plan reimbursement for Hemgenix (etranacogene dezaparvovec) for the treatment of eligible adults with haemophilia B (congenital factor IX deficiency) who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
